MX2020013574A - Pharmaceutical composition for oral administration, including an inhibitor of the proton pump with improved absorption. - Google Patents

Pharmaceutical composition for oral administration, including an inhibitor of the proton pump with improved absorption.

Info

Publication number
MX2020013574A
MX2020013574A MX2020013574A MX2020013574A MX2020013574A MX 2020013574 A MX2020013574 A MX 2020013574A MX 2020013574 A MX2020013574 A MX 2020013574A MX 2020013574 A MX2020013574 A MX 2020013574A MX 2020013574 A MX2020013574 A MX 2020013574A
Authority
MX
Mexico
Prior art keywords
inhibitor
pharmaceutical composition
oral administration
proton pump
improved absorption
Prior art date
Application number
MX2020013574A
Other languages
Spanish (es)
Inventor
Rete Jesús Montoya
Original Assignee
Laboratorios Liomont S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Liomont S A De C V filed Critical Laboratorios Liomont S A De C V
Priority to MX2020013574A priority Critical patent/MX2020013574A/en
Publication of MX2020013574A publication Critical patent/MX2020013574A/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

The present invention discloses a pharmaceutical composition for oral administration containing a proton pump inhibitor with enhanced absorption, providing at least the same performance as a MUPS system. Also, said composition gives stability and enhances the dissolution of said inhibitor through simple technology, improving the feasibility of its reproduction used for treating symptoms and diseases related to gastric acid.
MX2020013574A 2020-12-11 2020-12-11 Pharmaceutical composition for oral administration, including an inhibitor of the proton pump with improved absorption. MX2020013574A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2020013574A MX2020013574A (en) 2020-12-11 2020-12-11 Pharmaceutical composition for oral administration, including an inhibitor of the proton pump with improved absorption.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2020013574A MX2020013574A (en) 2020-12-11 2020-12-11 Pharmaceutical composition for oral administration, including an inhibitor of the proton pump with improved absorption.

Publications (1)

Publication Number Publication Date
MX2020013574A true MX2020013574A (en) 2021-09-02

Family

ID=86316713

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013574A MX2020013574A (en) 2020-12-11 2020-12-11 Pharmaceutical composition for oral administration, including an inhibitor of the proton pump with improved absorption.

Country Status (1)

Country Link
MX (1) MX2020013574A (en)

Similar Documents

Publication Publication Date Title
NO20080357L (en) Pharmaceutical compositions for modified delivery, as well as methods for preparing the same
CY1116463T1 (en) Combination therapy for the therapeutic treatment of Protein Deficiency Disorders
BR112015001419A2 (en) compound, pharmaceutical composition, and methods for inhibiting romk in a patient, causing diuresis, natriuresis, or both, and for treating one or more disorders.
BR112012007412A2 (en) orally transformable tablets.
EA201590836A1 (en) COMPOSITIONS WITH LOW DOSE OF PANCRELIPASE AND INTESTINAL COATING
BRPI0706676B8 (en) use of an aqueous solution with redox potential
MX2009004475A (en) Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same.
EA201270666A1 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING URIC ACID LEVEL
MX2009003372A (en) Non-mucoadhesive film dosage forms.
BRPI0508254A (en) methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
BRPI0415953B8 (en) controlled release dosage formulation and set of controlled release dosage forms
RU2017134443A (en) METHOD OF TREATMENT WITH USE OF TRADIPTANT
MX2012005689A (en) Arachidonic acid analogs and methods for analgesic treatment using same.
DE60108489D1 (en) COMBINATION THERAPIES WITH VULNERABLE ACTIVITY
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
BR112022009283A2 (en) METHODS OF TREATMENT OF SMALL CELL LUNG CANCER WITH LURBINECTEDIN FORMULATIONS
EA202190115A1 (en) FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS FOR THEIR PREPARATION
MX2010004556A (en) Pharmaceutical formulation of clavulanic acid.
RU2008122964A (en) Azithromycin for the treatment of granulomatous pink (red) acne
CR20230018A (en) Acalabrutinib maleate dosage forms
MX2020013574A (en) Pharmaceutical composition for oral administration, including an inhibitor of the proton pump with improved absorption.
MX2013001279A (en) Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.
SE0301885D0 (en) New use IV
BR112022019338A2 (en) MIGRAINE PREVENTIVE TREATMENT
CY1113544T1 (en) Pharmaceutical compositions comprising a combination formed by the antimicrobial agent CIPROFLOXACIN AND ANTIOXIDANT AGENT ASCORBIC ACID FOR THE TREATMENT OF INFECTIONS OF URINARY SYSTEM